Pfizer Inc. has announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback